本帖最后由 老马 于 2013-3-13 13:43 编辑 ; @9 ~, b! z( T% i X& X# b
3 z$ L; E U4 p健择（吉西他滨）+顺铂+阿瓦斯汀' Q0 P# L/ f! r( C1 H% G2 v
Gemzar +Cisplatin + Avastin* w; y/ X) B, Y+ T% v' U
http://annonc.oxfordjournals.org/content/21/9/1804.full
0 a& u& B& g' AOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 7 O( r5 m, y0 q& [
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 4 O R0 i6 S; ^5 B; {. w8 B
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 B2 Z5 O) N; Y5 S
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 925)
2 K! N3 ^0 D0 f4 W0 Z: `& q5 \华为网盘附件：
$ d; X/ r. Z" ~4 P- @【华为网盘】ava.JPG
2 V( B$ O1 p, R8 l |
显身卡
